FDA decision for Gilead’s once daily HIV pill BIC/LEN, PDUFA date August 27, 2026
Quick Trade Info
Upcoming catalystThe event that could move the share price.
FDA PDUFA decision on bictegravir 75 mg plus lenacapavir 50 mg (BIC/LEN) for HIV treatment. Thursday, August 27, 2026. The FDA does not publish a decision time.
Main stock affectedThe company the event affects most directly.
GILD, Gilead Sciences, Inc. Live data verification $145.17 last, timestamp 2026-08-20 17:36:37 UTC, regular session.
Expected stock reactionWhich way we expect the share price to go after the event. Positive means it rises, Negative means it falls, Mixed means it could go either way.
Positive. Pre-news action Buy. High probability of approval supported by two positive Phase 3 switch studies and priority review. Defined risk with partial size or a call spread.
Catalyst confidenceHow sure we are that the event happens as described. Scored out of 100. Higher means more sure.
High that a decision occurs on August 27. Moderate risk of a short extension if last‑minute labeling or CMC items arise.
Stock-reaction confidenceHow sure we are that the stock reacts the way we expect. Scored out of 100. Higher means more sure.
Medium. Gilead is large cap, so the move should be modest but positive if approval is clean. More Info
When the market will reactThe moment the price is likely to move, such as at the announcement or at the next market open.
Primary reaction on Thursday, August 27, 2026, either intraday if a press release posts during market hours, or after hours with price discovery in the next trading session. Follow through over 1 to 3 sessions as analysts update models. Fundamental effect Adds a new branded switch option that can extend Gilead’s HIV leadership. BIC/LEN targets virologically suppressed patients who want a simpler daily pill. Approval can slow competitor share gains and lengthen the revenue tail of the HIV franchise.
Market expectations and forecastWhat investors already expect from this event, and the numbers being forecast.
Expectation: approval on first cycle. Evidence: priority review granted, and Phase 3 ARTISTRY-1 and ARTISTRY-2 met noninferiority at 48 weeks with very low virologic failure rates near 1 percent. Historical NDA to approval rates are about 90 percent across diseases, and roughly 93 percent for infectious disease filings. My base case approval probability is 85 to 90 percent. Recent stock setup Shares rose after Q2 2026 results and guidance raise in early August, with HIV sales strength highlighted. Volume expanded on earnings. Peers in HIV, like GSK’s US ADR and Merck, have traded mixed in August. Priced-in level Medium. The date is public and partially in models, but numbers do not include launch contribution and label specifics. The prior move was mostly about earnings, not this decision. Expected move Options for the week around the date imply roughly a 4.5 to 5.5 percent one week move. Example math: price 145, implied volatility near 37 to 40 percent, time 7 days. 145 × 0.38 × sqrt(7/365) ≈ 7.6 points, about 5 percent. Surprise required A clean approval without restrictive labeling or drug interaction limits, plus early launch timing, would be needed for an upside move beyond about 5 percent. Any delay or Complete Response Letter would likely exceed the downside implied move. Positive scenario Approval with a broad switch label for virologically suppressed adults, no REMS beyond standard, and manageable drug interaction language. Management guides to a near term launch timeline and reiterates HIV growth of high single digits or better. Neutral scenario Approval, but with notable drug interaction or population carve outs that limit near term uptake. Street waits for formulary wins and early script data before re rating. Negative scenario PDUFA extension by three months due to new submissions late in the cycle, a manufacturing or labeling issue, or a Complete Response Letter requesting more data. Stock gives back recent strength. Why the stock is connected This is Gilead’s own NDA. A yes adds a new daily pill that combines bictegravir, a leading integrase inhibitor, with lenacapavir, a capsid inhibitor already approved in other settings. The switch population is large in HIV care. Even modest penetration can add meaningful revenue and protect the core Biktarvy base. Simple example: if 1 out of every 20 Biktarvy patients eventually switches to BIC/LEN, Gilead still keeps that patient on a Gilead regimen instead of risking a move to a rival.
Other affected stocksOther companies that could move on the same news, such as suppliers and competitors.
MRK, as the key partner and competitor in long acting HIV regimens including once weekly oral programs. GSK, via ViiV Healthcare’s HIV portfolio, as a competitor in treatment and prevention. Impact strength and duration Medium impact, long term. The stock move should be modest on day one, but the revenue and share defense effects build over multiple years. Underappreciated factor Cannibalization can still be a net positive. Moving a patient from Biktarvy to BIC/LEN keeps revenue inside Gilead and may extend the brand life against weekly oral and injectable competitors. Also, if the drug interaction section is cleaner than expected, payers may be quicker to adopt. Post-news confirmation plan If approved, look for a close above 147 on at least 1.5 times the 20 day average volume. That would confirm demand. Hold 2 to 6 weeks while watching early access, payer updates, and first script color.
What else lands that dayOther news and events on the same day that could push the price around, and whether they help this trade, bury it, or work against it.
27 August 2026 is the opening day of the Federal Reserve symposium at Jackson Hole, which runs to 29 August. Jackson Hole is not a data release, it is where policy direction gets signalled, and it moves the whole index rather than any one sector. Alongside it the day carries initial jobless claims at 12:30 UTC and, at 14:00 UTC, the Bureau of Labor Statistics employment projections and worker displacement releases, neither of which trades. An FDA approval for a once-daily HIV pill is a company-specific event at a company large enough to sit in every index fund, so the two are not competing for the same buyer, but they are competing for the same attention and the same headlines. Net effect: the news should be read cleanly by the people who follow Gilead, and the share price will still carry whatever the index does that day. What to expect on the day. A PDUFA date is a deadline rather than an appointment, so the decision can arrive at any hour or slip entirely, and there is no scheduled minute to trade around. If it lands while Jackson Hole is being reported, expect the first move to be diluted by index direction rather than clean. Judge the reaction on the close and on the following session, not on the first thirty minutes.
Main risksWhat could go wrong, and what would prove this call wrong.
A three month PDUFA extension. Label restrictions, especially around CYP3A inducer interactions with lenacapavir, that slow uptake. Manufacturing or supply issues. A broader rotation out of large cap pharma that overwhelms single stock news. Any other important factors 1) Timing of the press release matters for gap risk. Size positions accordingly. 2) If you prefer defined risk, a September monthly 145 by 155 call spread targets a 4 to 6 percent move while capping downside to the debit. 3) Watch competitors’ commentary. If rivals guide to faster share gains, some approval benefit could be offset.
For information only · not financial advice.